Skip to main content
Premium Trial:

Request an Annual Quote

IBM Signs Partners to Accelerate Cancer Research

NEW YORK, Nov. 8 (GenomeWeb News) - IBM has signed separate agreements with a number of research centers to accelerate cancer research, diagnosis and treatment, the company said today.

 

The agreements were signed with Memorial Sloan-Kettering Cancer Center, the Molecular Profiling Institute, and the CHU Sainte-Justine Research Center- Mother and Child University Hospital Center.

 

IBM and Sloan-Kettering will build a system to study long-term cancer-related illnesses, identify disease trends, and determine success rates. With a $3 million technology grant from IBM, Sloan-Kettering will also integrate its hospital data and create a searchable database for pathology reports.

 

IBM and Molecular Profiling will jointly develop diagnostic technology. Advances from Molecular Profiling's partnership with Translational Genomics Research Institute will be shared with IBM, the company said.

 

IBM and CHU, a teaching hospital affiliated with the University of Montreal, will build a system based on IBM's Clinical Genomics Solution to define the genetic markers for acute lymphoblastic leukemia.

 

Financial details were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.